ANTIBACTERIAL DRUGS MARKET ANALYSIS

Antibacterial Drugs Market, by Drug Class (β-lactams, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulfonamides, Phenicols, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI177
Pages :185
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Antibacterial Drugs Market– Restraints

High cost of vaccine development is expected to hinder growth of market over the forecast period. For instance, on June 22, 2021, an article published in BMJ, a scientific journal stated about high costing of vaccine. The Centers for Disease Control and Prevention (CDC) purchased bulk vaccine through agreements for the 2020-21 flu season, the CDC purchased seven million doses directly from manufacturers for US$ 100 Mn each a higher price than it had in previous year 2020.

Increasing product approvals from regulatory bodies is expected to drive global antibacterial drugs market growth over the forecast period.

Antibacterial drugs market is expected to witness significant growth over the forecast period, owing to increasing focus of market players on gaining product approvals from regulatory bodies. For instance, in June 2021, Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved the company’s supplemental new drug application (sNDA) for the oral-only dosing regimen of NUZYRA for the treatment of adults with community-acquired bacterial pneumonia (CABP)